IL13 and chronic asthma: Through in vivo studies with IL-13 TG mice displaying a majority of the features seen in chronic asthma patients, we confirmed the intratracheal delivery method retained anti-asthmatic abilities, while ensuring the absence of xenogeneic effects, as already proven by previous studies27,28.